We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$5.15B
Cap. Flow %
-877.82%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$4.99B
2
MRK icon
Merck
MRK
+$24.8M
3
ABBV icon
AbbVie
ABBV
+$23.3M
4
AGN
Allergan Inc
AGN
+$23M
5
JNJ icon
Johnson & Johnson
JNJ
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 63.04%
2 Technology 5.1%
3 Industrials 3.71%
4 Energy 1.9%
5 Consumer Discretionary 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNVC
101
DELISTED
GenVec, Inc.
GNVC
$1.2M 0.2%
55,833
– –
MNKD icon
102
PUT
MannKind Corp
MNKD
$1.21B
$1.16M 0.2%
60,000
– –
GNMX
103
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.14M 0.19%
+225,000
New +$1.11M
NBIX icon
104
Neurocrine Biosciences
NBIX
$16.8B
$1.12M 0.19%
+50,000
New +$947K
KMDA icon
105
Kamada
KMDA
$412M
$1.09M 0.19%
+293,727
New +$1.11M
CARM
106
DELISTED
Carisma Therapeutics
CARM
$1.03M 0.18%
+4,356
New +$977K
RPRX
107
DELISTED
Repros Therapeutics Inc.
RPRX
$997K 0.17%
+100,000
New +$853K
LUMO
108
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$994K 0.17%
+2,778
New +$827K
ZSPH
109
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$860K 0.15%
20,682
– –
CASC
110
DELISTED
Cascadian Therapeutics, Inc.
CASC
$813K 0.14%
71,333
– –
JUNO
111
DELISTED
Juno Therapeutics, Inc.
JUNO
$783K 0.13%
+15,000
New +$671K
SVRA icon
112
Savara
SVRA
$1.12B
$770K 0.13%
+19,641
New +$686K
PTN
113
Palatin Technologies
PTN
$13.7M
$759K 0.13%
832
-36
-4% -$33.2K
TLPH icon
114
Talphera
TLPH
$66.4M
$673K 0.11%
5,000
-9,492
-65% -$1.23M
ARDX icon
115
Ardelyx
ARDX
$1.22B
$618K 0.11%
+32,700
New +$757K
KBIO
116
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$605K 0.1%
43,695
– –
MLNX
117
DELISTED
Mellanox Technologies, Ltd.
MLNX
$535K 0.09%
+12,517
New +$543K
ICL icon
118
ICL Group
ICL
$6.53B
$291K 0.05%
40,116
-1,339,884
-97% -$9.37M
ARCT icon
119
Arcturus Therapeutics
ARCT
$164M
$144K 0.02%
+5,500
New +$175K
XLB icon
120
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.5B
$116K 0.02%
+100,000
New +$2.42M
NVAX icon
121
Novavax
NVAX
$1.2B
$9K ﹤0.01%
+77
New +$8.05K
GSK icon
122
CALL
GSK
GSK
$104B
$7K ﹤0.01%
233,040
– –
ABBV icon
123
AbbVie
ABBV
$443B
– –
-403,550
Closed -$23.3M
AFMD
124
DELISTED
Affimed
AFMD
– –
-15,000
Closed -$945K
AGIO icon
125
Agios Pharmaceuticals
AGIO
$1.79B
– –
-405
Closed -$25K
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $5.15B in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Isramco Inc, cutting an estimated $4.99B.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.